Company intelligence / Profile preview

BioLamina

Sundbyberg, Stockholm County, Swedenbiolamina.com ↗

Ownership: Private
Development stage: Other

Overview

BioLamina’s Biolaminin® matrices are commercially available and widely adopted in academic and industrial settings to support robust expansion, maintenance, and differentiation of human cells. Their products are animal-origin free, chemically defined, batch-to-batch consistent, ISO 9001 certified. They enable reproducible results in both basic research and clinical manufacturing.

Modalities: Cell culture matrix proteins
Industry: Chemicals & Materials

Partnerships

No specific major pharma/biotech partnerships listed publicly; collaborates with academic institutions globally

Beyond the preview

Go deeper on BioLamina.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioLamina.